Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Graft vs Host Disease 1

Interventions

Imatinib Mesylate 5nilotinib 3ponatinib 2thymoglobulin 1enasidenib 1bosutinib 1Transplantation 1Standard of Care 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Hematopoietic Stem Cell Transplantation 1Cytarabine 1Cyclosporine 1BID protein, human 1Azacitidine 1Antilymphocyte Serum 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid × Methylprednisolone Acetate × Clear all
NCT00568633 2019-09-24

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Stanford University

Phase 3 Terminated
58 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡